YSX TECH. CO. LTD to Hold Extraordinary General Meeting of Shareholders

GUANGZHOU, China, Oct. 05, 2026 (GLOBE NEWSWIRE) — YSX TECH. CO., LTD (NASDAQ: “YSXT”) (the “Company”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced that it will hold an extraordinary general meeting of shareholders (the “EGM”), on October 19, 2026 at 12:00 a.m. Eastern Time, at Room 102, Building 1, No. 22, Huazhou Road, Haizhu District, Guangzhou, Guangdong, China , for the purpose of considering and voting on the following proposals:

CPESN Names Sanjay Patel Luminary of the Year for 2026

Kansas City, Mo., Oct. 05, 2026 (GLOBE NEWSWIRE) — CPESN® USA, a clinically integrated, nationwide organization of pharmacy networks advancing community-based pharmacy practice, today announced that Sanjay Patel, RPh, has been named the recipient of the 2026 CPESN Luminary of the Year Award, sponsored by Prasco. 

Decent Holding Inc. Announces Closing of $1.23 Million Follow-on Offering

YANTAI, China, Oct. 05, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (the “Company”), a technology-driven provider of wastewater treatment and community-based senior health and elderly care services in China, today announced the closing of its previously announced follow-on offering to an institutional investor for the sale of (i) in a registered direct offering, 822,828 Class A ordinary shares, par value of $0.0025 per share, of the Company (the “Class A Ordinary Shares”) or, in lieu thereof, pre-funded warrants, at a purchase price of $1.50 per share; and (ii) in a concurrent private placement, unregistered warrants (the “Unregistered Warrants”) to purchase up to 822,828 Class A Ordinary Shares, with an exercise price of $1.50 per share (together, the “Securities”). The offering closed on October 05, 2026. 

Micropolis AI Robotics Receives NYSE American Notice Regarding Stockholders’ Equity Requirement

DUBAI, United Arab Emirates, Oct. 05, 2026 (GLOBE NEWSWIRE) — Micropolis AI Robotics (NYSE American: MCRP) (the “Company”) today announced that it received a letter from NYSE Regulation dated September 29, 2026, notifying the Company that it is not in compliance with the stockholders’ equity requirement in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”).

NOVAGOLD Files and Mails Materials for Special Meeting to Approve Proposed Acquisition of 100% of Donlin Gold

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — NOVAGOLD RESOURCES INC. (“NOVAGOLD” or the “Company”) (NYSE American, TSX: NG) today announced that it has filed and commenced mailing its management information circular and definitive proxy statement (the “Circular and Proxy Statement”) and related proxy materials (collectively, the “Meeting Materials”) for the special meeting of shareholders to be held on November 3, 2026 (the “Meeting”). At the Meeting, shareholders of record at the close of business on September 23, 2026 (the “Record Date”) will be asked to consider and, if deemed advisable, approve, with or without variation, (i) a special resolution (the “Arrangement Resolution”) approving a Plan of Arrangement (the “Arrangement”), relating to the transactions announced on July 22, 2026, pursuant to which, subject to the satisfaction of certain closing conditions, upon the consummation thereof, NovaGold Corporation, a newly incorporated Delaware company (“New NOVAGOLD”), would become the ultimate parent of NOVAGOLD and its subsidiaries and would acquire the 40% interest in Donlin Gold LLC (“Donlin Gold”) held by Paulson Advisers LLC and certain of its affiliates (collectively, “Paulson”) through Donlin Gold Holdings LLC (“Donlin Gold Holdings”)1, increasing NOVAGOLD’s ownership from 60% to 100% in its Tier One2 gold development project in Alaska (the “Transactions”), and (ii) the other resolutions summarized below, each of which is described in greater detail in the Circular and Proxy Statement.

Big Bear Gold Corp. Announces Change of Transfer Agent to Olympia Trust Company

Vancouver, BC, Oct. 05, 2026 (GLOBE NEWSWIRE) — Big Bear Gold Corp. (TSXV: BEAR) (the “Company” or “BEAR”) announces that Olympia Trust Company has replaced Computershare Trust Company as the Company’s transfer agent effective October 1, 2026.  Shareholders do not need to take any action in respect to the change in transfer agent.

All inquiries and correspondence relating to shareholders’ records, transfer of shares, lost certificates, changes of addresses or other inquiries related to shares should now be directed to Olympia Trust Company as follows:

One Fridge-Sized Satellite. A Grounded Rocket Program. A Project That Won’t Launch Until 2027. James Altucher Says Elon Musk’s Rivals Aren’t Close.

A new free presentation from the tech expert who has called some of the biggest tech stories of the past two decades explains that everyone chasing Musk into space is years behind.

A new free presentation from the tech expert who has called some of the biggest tech stories of the past two decades explains that everyone chasing Musk into space is years behind.

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight

The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward.

The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward.